LONDON, PHILADELPHIA and CAMBRIDGE, Mass., June 6
/PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that
it has completed its acquisition of Sirtris Pharmaceuticals, Inc. (Sirtris)
for approximately USD720 million (or approx. GBP362 million) through a cash
tender offer and merger of USD22.50 (or approx. GBP11.33) per share.
Through the acquisition of Sirtris, GSK has significantly enhanced its
metabolic, neurology, immunology and inflammation research efforts by
establishing a presence in the field of sirtuins, a recently discovered
class of enzymes that is believed to be involved in the ageing process.
Sirtris will become part of GSK's Drug Discovery organization, while
continuing to operate from laboratories in Cambridge, Massachusetts, as an
autonomous drug discovery unit. Christoph Westphal, CEO and Vice Chair of
Sirtris, and the management team will continue to lead this autonomous
unit.
About GSK
GSK -- one of the world's leading research-based pharmaceutical and
healthcare companies -- is committed to improving the quality of human life
by enabling people to do more, feel better and live longer. For company
information including a copy of this announcement and details of the
company's updated product development pipeline, visit GSK at http://www.gsk.com.
SOURCE GlaxoSmithKline
 back to top
Related links:
http://www.gsk.com
http://www.prnewswire.com/comp/801350.html/
CONTACT:
UK Media enquiries: Philip Thomson, Claire
Brough, Alice Hunt, or Gwenan White, 020-8047-5502; or US Media
enquiries: Nancy Pekarek, +1-215-751-7709, or Mary Anne Rhyne,
+1-919-483-2839, or Melinda Stubbee, +1-610-270-6247, or European
Analyst, Investor enquiries: David Mawdsley, 020-8047-5564, Sally
Ferguson, 020-8047-5543, or Gary Davies, 020-8047-5503, or US
Analyst, Investor enquiries: Frank Murdolo, +1-215-751-7002, or
Tom Curry, +1-215-751-5419, all of GlaxoSmithKline
|
